Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

CYCLACEL PHARMACEUTICALS INC
Mes dernières consult.
Most popular
  Report  
 SummaryNewsCalendarCompanyFinancialsConsensus 
Company
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company.It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases.The company builds a diversified biopharmaceutical... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
07:01aCyclacel Announces Notice of Grant of New European Patent Covering Sapacitabi..
GL
02/06Cyclacel Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference
GL
01/24Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Con..
GL
01/09Cyclacel Reviews 2017 Achievements and Announces Key Business Objectives for ..
GL
2017CYCLACEL PHARMACEUTICALS : Announces Presentation of Results From Phase 3 Seamle..
AQ
2017CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Departure of Directors..
AQ
2017CYCLACEL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Othe..
AQ
2017CYCLACEL PHARMACEUTICALS : Announces Presentation of Results From Phase 3 Seamle..
PU
2017Cyclacel Announces Presentation of Results From Phase 3 Seamless Study at As..
GL
2017CYCLACEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
AQ
More news
Sector news : Bio Therapeutic Drugs
02/15French pharma group Ipsen sees more asset purchases, U.S. growth
RE
02/15Oxford BioMedica wins second $100 million gene therapy contract
RE
02/14Bristol-Myers to pay $1.85 billion in cancer deal with Nektar
RE
02/14BRISTOL MYERS SQUIBB : Nektar to Partner on Cancer Therapy
DJ
02/13Drug copies ready to take next bite out of Roche's cancer sales
RE
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016Midday Gainers / Losers 
2016Midday Gainers / Losers 
2016Cyclacel's lead product candidates show encouraging results in early-stage st.. 
2016HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am 
2016Some Ideas For The Next Celator 
Income Statement Evolution
Consensus
 
Mean consensus
Number of Analysts 0
Average target price 7,00 $
Spread / Average Target 338%
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICALS INC19
GILEAD SCIENCES14.21%105 702
VERTEX PHARMACEUTICALS4.94%40 647
REGENERON PHARMACEUTICALS-12.04%35 686
BIOVERATIV INC91.99%11 211
GENMAB4.28%10 637